1. Yamamura D, Xu J. (2021) Update on Pulmonary Cryptococcosis. Mycopathologia (In press)
2. Chen M, Xu N, Xu J. (2020) Cryptococcus neoformans meningitis cases among China’s HIV-infected population may have been severely under-reported. Mycopathologia. 185, 971–974.
3. Husain S, Wagener MM, Singh N. (2001) Cryptococcus neoformans Infection in Organ Transplant Recipients: Variables Influencing Clinical Characteristics and Outcome. Emerg Infect Dis. 7, 375–381.
4. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. (2009) Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun. 77, 120–127.
5. Speed B, Dunt D. (1995) Clinical and Host Differences Between Infections with the Two Varieties of Cryptococcus neoformans. Clin Infect Dis. 21, 28–34.
6. Mitchell TG, Perfect JR. (1995) Cryptococcosis in the era of AIDS - 100 years after the discovery of Crypotcoccus neoformans. Clin. Microbiol. Rev. 8, 515–548.
7. Damasceno-Escoura, A., de Souza, M.L., de Oliveira Nunes, F. et al. (2019) Epidemiological, Clinical and Outcome Aspects of Patients with Cryptococcosis Caused by Cryptococcus gattii from a Non-endemic Area of Brazil. Mycopathologia 184, 65–71.
8. García-Rodas R, Zaragoza O. (2012) Catch me if you can: Phagocytosis and killing avoidance by Cryptococcus neoformans. FEMS Immunol. Med. Microbiol. 64, 147–161.
9. Fang FC. (2004) Antimicrobial reactive oxygen and nitrogen species: Concepts and controversies. Nat. Rev. Microbiol. 2(10), 820–32.
10. Zaragoza O, Chrisman CJ, Castelli MV, Frases S, Cuenca-Estrella M, Rodríguez-Tudela JL, et al. (2008) Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol. 10, 2043–2057.
11. Nathan CF, Hibbs JB. (1991) Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol. 3, 65–70.
12. Naslund PK, Miller WC, Granger DL. (1995) Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect Immun. 63, 1298–1304.
13. Lovchik JA, Lyons CR, Lipscomb MF. (1995) A role for gamma interferon-induced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am J Respir Cell Mol Biol. 13, 116–124.
14. Tohyama M, Kawakami K, Futenma M, Saito A. (2007) Enhancing effect of oxygen radical scavengers on murine macrophage anticryptococcal activity through production of nitric oxide. Clin Exp Immunol. 103, 436–141.
15. Lee SC, Kress Y, Zhao ML, Dickson DW, Casadevall A. (1995) Cryptococcus neoformans survive and replicate in human microglia. Lab Investig. 73, 871–879.
16. Alvarez M, Casadevall A. (2006) Phagosome Extrusion and Host-Cell Survival after Cryptococcus neoformans Phagocytosis by Macrophages. Curr Biol. 16, 2161–2165.
17. Barchiesi F, Cogliati M, Esposto MC, Spreghini E, Schimizzi AM, Wickes BL, et al. (2005) Comparative analysis of pathogenicity of Cryptococcus neoformans serotypes A, D and AD in murine cryptococcosis. J Infect. 51, 10–16.
18. Irokanulo EAO, Akueshi CO. (1995) Virulence of Cryptococcus neoformans serotypes A, B, C and D for four mouse strains. J Med Microbiol. 43, 289–293.
19. Casadevall A, Rosas AL, Nosanchuk JD. (2000) Melanin and virulence in Cryptococcus neoformans. Curr. Opin. Microbiol. 3, 354–358.
20. Charlier C, Chrétien F, Baudrimont M, Mordelet E, Lortholary O, Dromer F. (2005) Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol. 166, 421–432.
21. Jacobson ES, Tinnell SB. (1993) Antioxidant function of fungal melanin. J. Bacteriol. 175, 7102–7104.
22. Emery HS, Shelburne CP, Bowman JP, Fallon PG, Schulz CA, Jacobson ES. (1994) Genetic study of oxygen resistance and melanization in Cryptococcus neoformans. Infect. Immun. 62, 5694–5697.
23. Wang Y, Aisen P, Casadevall A. (1995) Cryptococcus neoformans melanin and virulence: Mechanism of action. Infect Immun. 63, 3131–3136.
24. Liu L, Tewari RP, Williamson PR. (1999) Laccase protects Cryptococcus neoformans from antifungal activity of alveolar macrophages. Infect Immun. 67, 6034–6039.
25. Kwon-Chung KJ, Polacheck I, Popkin TJ. (1982) Melanin-lacking mutants of Cryptococcus neoformans and their virulence for mice. J Bacteriol. 150, 1414–1421.
26. Kwon-Chung KJ, Rhodes JC. (1986) Encapsulation and melanin formation as indicators of virulence in Cryptococccus neoformans. Infect Immun. 51, 218–223.
27. Wang Y, Casadevall A. (1994) Susceptibility of melanized and nonmelanized Cryptococcus neoformans to nitrogen- and oxygen-derived oxidants. Infect. Immun. 62, 3004–3007.
28. Kozel TR, Gotschlich EC. (1982) The capsule of Cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages. J Immunol. 129, 1675–1680.
29. Tucker SC, Casadevall A. (2002) Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc Natl Acad Sci (USA). 99, 3165–3170.
30. Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A. (2009) The Capsule of the Fungal Pathogen Cryptococcus neoformans. Adv. Appl. Microbiol. Academic Press; p. 133–216.
31. Bulmer GS, Sans MD, Gunn CM. (1967) Cryptococcus neoformans. I. Nonencapsulated mutants. J Bacteriol. 94, 1475–1479.
32. Bulmer GS, Sans MD. (1967) Cryptococcus neoformans. II. Phagocytosis by human leukocytes. J Bacteriol 94, 1480–1483.
33. Kozel TR, Cazin J. (1971) Nonencapsulated Variant of Cryptococcus neoformans I. Virulence Studies and Characterization of Soluble Polysaccharide. Infect Immun. 3, 287–294.
34. Stearns SC. (1989) The Evolutionary Significance of Phenotypic Plasticity. Bioscience. 39, 436–445.
35. Guerrero A, Jain N, Goldman DL, Fries BC. (2006) Phenotypic switching in Cryptococcus neoformans. Microbiology. 152, 3-9.
36. Yan Z, Li X, Xu J. (2002) Geographic distribution of mating type alleles of Cryptococcus neoformans in four areas of the United States. J Clin Microbiol. 40, 965–972.
37. Samarasinghe H, Aceituno-Caicedo D, Cogliati M, Kwon-Chung KJ, Rickerts V, Velegraki A, et al. (2018) Genetic Factors and Genotype-Environment Interactions Contribute to Variation in Melanin Production in the Fungal Pathogen Cryptococcus neoformans. Sci Rep. 8, 9824.
38. Sun S, Xu J. (2009) Chromosomal Rearrangements between Serotype A and D Strains in Cryptococcus neoformans. PLoS One. 4, e5524.
39. Nielsen K, Cox GM, Wang P, Toffaletti DL, Perfect JR, Heitman J. (2003) Sexual cycle of Cryptococcus neoformans var. grubii and Virulence of congenic a and α isolates. Infect Immun. 71, 4831–4841.
40. Toffaletti DL, Rude TH, Johnston SA, Durack DT, Perfect JR. (1993) Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. J Bacteriol 175, 1405–1411.
41. Hua W, Vogan A, Xu J. (2019) Genotypic and Phenotypic Analyses of Two “Isogenic” Strains of the Human Fungal Pathogen Cryptococcus neoformans var. neoformans. Mycopathologia. 184, 195–212.
42. Vogan AA, Khankhet J, Xu J. (2013) Evidence for Mitotic Recombination within the Basidia of a Hybrid Cross of Cryptococcus neoformans. PLoS One. 8, e62790
43. Vogan AA, Xu J. (2014) Evidence for genetic incompatibilities associated with post-zygotic reproductive isolation in the human fungal pathogen Cryptococcus neoformans. Genome 57, 335–344.
44. Brandt ME, Hutwagner LC, Klug LA, Baughman WS, Rimland D, Graviss EA, et al. (1996) Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. J Clin Microbiol. 34, 912-917.
45. Samarasinghe H, Vogan A, Pum N, Xu J. (2020) Patterns of allele distribution in a hybrid population of the Cryptococcus neoformans species complex. Mycoses 63, 275–283.
46. Vogan AA, Khankhet J, Samarasinghe H, Xu J. (2016) Identification of QTLs associated with virulence related traits and drug resistance in Cryptococcus neoformans. G3: Genes, Genomes, Genet. 6, 2745–2759.
47. Bryan RA, Zaragoza O, Zhang T, Ortiz G, Casadevall A, Dadachova E. (2005) Radiological studies reveal radial differences in the architecture of the polysaccharide capsule of Cryptococcus neoformans. Eukaryot Cell. 4, 465–475.
48. Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. (1956) Colorimetric Method for Determination of Sugars and Related Substances. Anal Chem 28, 350–356.
49. Valladares F, Sanchez-Gomez D, Zavala MA. (2006) Quantitative estimation of phenotypic plasticity: bridging the gap between the evolutionary concept and its ecological applications. J Ecol 94, 1103–1116.
50. Guerrero A, Jain N, Wang X, Fries BC. (2010) Cryptococcus neoformans variants generated by phenotypic switching differ in virulence through effects on macrophage activation. Infect Immun. 78, 1049–1057.
51. Fries BC, Goldman DL, Cherniak R, Ju R, Casadevall A. (1999) Phenotypic switching in Cryptococcus neoformans results in changes in cellular morphology and glucuronoxylomannan structure. Infect Immun 67, 6076–6083.
52. Goldman DL, Fries BC, Franzot SP, Montella L, Casadevall A. (1998) Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc Natl Acad Sci (USA). 95, 14967–14972.
53. Fries BC, Taborda CP, Serfass E, Casadevall A. (2001) Phenotypic switching of Cryptococcus neoformans occurs in vivo and influences the outcome of infection. J Clin Invest. 108, 1639–1648.
54. Littman ML, Tsubura E. (1959) Effect of Degree of Encapsulation upon Virulence of Cryptococcus neoformans. Exp Biol Med 101, 773–777.
55. McFadden DC, Fries BC, Wang F, Casadevall A. (2007) Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans. Eukaryot Cell. 6, 1464–1473.
56. Sabiiti W, Robertson E, Beale MA, Johnston SA, Brouwer AE, Loyse A, et al. (2014) Efficient phagocytosis and laccase activity affect the outcome of HIV-associated cryptococcosis. J Clin Invest. 124, 2000–2008.
57. Robertson EJ, Najjuka G, Rolfes MA, Akampurira A, Jain N, Anantharanjit J, et al. (2014) Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis. J Infect Dis 209, 74–82.
58. Xu J, Luo G, Vilgalys R, Brandt ME, and Mitchell TG. (2002) Multiple origins of hybrid strains of Cryptococcus neoformans with serotype AD. Microbiology 148:203-212.
59. Samarasinghe H, You M, Jenkinson TS, Xu J, James TY. (2020) Hybridization Facilitates Adaptive Evolution in Two Major Fungal Pathogens. Genes 11, 101.
60. Dong K, You M, Xu J. (2019) Genetic Changes in Experimental Populations of a Hybrid in the Cryptococcus neoformans Species Complex. Pathogens 9, 3.
61. Polacheck I, Platt Y, Aronovitch J. (1990) Catecholamines and virulence of Cryptococcus neoformans. Infect Immun 58, 2919–2922.
62. Alspaugh JA, Granger DL. (1991) Inhibition of Cryptococcus neoformans replication by nitrogen oxides supports the role of these molecules as effectors of macrophage-mediated cytostasis. Infect Immun. 59, 2291–2296.
63. Xie Q, Kawakami K, Kudeken N, Zhang T, Qureshi MH, Saito A. (1997) Different Susceptibility of Three Clinically Isolated Strains of Cryptococcus neoformans to the Fungicidal Effects of Reactive Nitrogen and Oxygen Intermediates: Possible Relationships with Virulence. Microbiol Immunol. 41, 725–731.
64. Cox GM, Harrison TS, McDade HC, Taborda CP, Heinrich G, Casadevall A, et al. (2003) Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages. Infect Immun. 71, 173–180.
65. Akhter S, McDade HC, Gorlach JM, Heinrich G, Cox GM, Perfect JR. (2003) Role of alternative oxidase gene in pathogenesis of Cryptococcus neoformans. Infect Immun 71, 5794–5802.